In a post-hoc analysis of the REDHART study, Buckley et al. concluded that IL-1 could be a potential key mediator of inflammation in heart failure and CKD as they have observed a fall in inflammation markers after the use of anakinra, a recombinant human IL-1 receptor antagonist. Here, IL1B is linked to chronic kidney disease.